Meta Pixel
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

News and Announcements

OZ Medicann to expand corporate structure enhancing its ability to provide products for the Australian and  International markets

  • Published February 28, 2018 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

OZ Medicann Pty Ltd is enhancing its ability to provide class-leading, patient-centric, development and supply medicinal cannabis products for the Australian and  International markets

The restructure which will involve the creation of a new head company, Oz Medicann Group Pty Ltd, under which will reside:

  • Oz Medicann P/L focused primarily on the cultivation, research, production and supply of
    medicinal cannabis solutions
  • Educann P/L which will deliver education, certification and accreditation to the medical
    practitioners and medicinal cannabis prescribers, and
  • Hemp OZ P/L commercialise related products and services that are derived from the cannabis
    plant.

All entities will generate sustainable revenue that will fund the short and medium and longer terms growth of the Group.

Unlike other medicinal cannabis companies, the OZ Medicann Group will control the entire medicinal cannabis supply chain, from seedling to researcher to patient. The objective of the OZ Medicann Group is to deliver the highest quality medicinal and therapeutic solutions to those who most need them the most – the Patients. With its focus on the sustainable production of high-quality medicinal cannabis solutions, the company will derive revenue from all sources in order to support this outcome.

The OZ Medicann Group is also pleased to announce the appointment of Lucy Haslam to its Board of Directors. Having Lucy on the Board further cements the Group’s commitment to patient-centric research and production and supply of medicinal cannabis solutions. Lucy is the leading advocate and driving force behind the legalisation of medicinal cannabis in Australia and we are thrilled to have Lucy join our team.

The OZ Medicann Group is also pleased to announce, in partnership with United in Compassion, the commencement soon of the largest patient-centric research on medicinal cannabis use in this country. A final announcement will be made shortly on the research partner who will undertake the survey.

The Group’s licence applications are with the Office of Drug Control and are being assessed for production, supply and research. The Group’s growing facility preparations are underway anticipated for quarter 4.

 

About OZ Medicann

OZ Medicann is a leading Australian Cannabis and Hemp cultivator that produces medicinal solutions, consumer products and education programs for medical practitioners.

Request Offer

Capital Insights
Navigating the Market Inflection Point: Exclusive Investor & Founder Meetups Across Australia

The market is at a genuine inflection point in mid-2025, with conflicting signals from AI breakthroughs and geopolitical shifts. This blog announces exclusive, intimate investor and founder meetups across Australia, designed to cut through the noise, reveal unfiltered truths about the H2 2025 outlook, and map the “smart money migration” to position participants for strategic advantage.

Capital Insights
Beyond the Hype: Strategic Digital Asset Investing for a New Financial Era

The financial world is undergoing a profound transformation driven by Digital Assets. Learn why hundreds of billions are pouring into new digital infrastructure, with stablecoins now outperforming Mastercard/Visa in transaction volume. This article guides investors beyond the hype to strategic digital asset investing, exploring yield, DePIN, DeFi, and AI+Blockchain for the new financial era. Discover more at Venture & Capital SYDNEY 2025.

Join over 45,000+ sophisticated investors

Join Now